CB
NBIX icon

Commerce Bank’s Neurocrine Biosciences NBIX Stock Holding History

Commerce Bank’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.75M Buy
13,292
+11,680
+725% +$1.55M 0.01% 575
2025
Q4 		$229K Buy
1,612
+32
+2% +$4.64K ﹤0.01% 1164
2025
Q3 		$222K Buy
+1,580
New +$214K ﹤0.01% 1166
2024
Q4 		– Sell
-4,199
Closed -$484K – 1215
2024
Q3 		$484K Buy
4,199
+108
+3% +$14.8K ﹤0.01% 896
2024
Q2 		$563K Buy
+4,091
New +$561K ﹤0.01% 808
2022
Q2 		– Sell
-2,166
Closed -$203K – 1181
2022
Q1 		$203K Buy
+2,166
New +$184K ﹤0.01% 1134
2021
Q3 		– Sell
-6,176
Closed -$601K – 1175
2021
Q2 		$601K Sell
6,176
-12
-0.2% -$1.15K ﹤0.01% 766
2021
Q1 		$602K Buy
6,188
+280
+5% +$29.4K ﹤0.01% 749
2020
Q4 		$567K Buy
5,908
+2,065
+54% +$199K ﹤0.01% 726
2020
Q3 		$370K Buy
3,843
+63
+2% +$7.29K ﹤0.01% 788
2020
Q2 		$461K Sell
3,780
-12
-0.3% -$1.33K ﹤0.01% 694
2020
Q1 		$328K Buy
3,792
+1,177
+45% +$115K ﹤0.01% 731
2019
Q4 		$281K Buy
+2,615
New +$274K ﹤0.01% 847

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Commerce Bank's NBIX Position: Q1 2026 in Review

Commerce Bank increased its Neurocrine Biosciences (NBIX) stake by 725% in Q1 2026, buying an estimated $1.55M and bringing the position to 13,292 shares worth $1.75M. The position accounts for 0.01% of the portfolio, ranked #575.

Commerce Bank first reported a position in NBIX in Q4 2019 and has held it in 13 quarters since. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Commerce Bank held 13,292 shares of Neurocrine Biosciences worth $1.75M as of Q1 2026.
  • Commerce Bank bought 11,680 Neurocrine Biosciences shares in Q1 2026, an estimated $1.55M.
  • Neurocrine Biosciences made up 0.01% of Commerce Bank's portfolio in Q1 2026, its #575 holding.
  • Commerce Bank first reported a position in Neurocrine Biosciences in Q4 2019 and has held it in 13 quarters since.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Commerce Bank's 13F filing for Q1 2026, filed 11 May 2026.